Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefpodoxime proxetil + ofloxacin
- Development stage
- Unknown
- Lead developer
- Thrift Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IPOD-O is an oral fixed-dose combination antibiotic tablet containing cefpodoxime proxetil, a third-generation cephalosporin, and ofloxacin, a second-generation fluoroquinolone. Developed and marketed by Thrift Pharmaceuticals, this combination is approved for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other systemic bacterial infections. Cefpodoxime proxetil acts as a prodrug that is hydrolyzed to active cefpodoxime, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Ofloxacin inhibits bacterial DNA replication by targeting DNA gyrase and topoisomerase IV. Together, these two agents provide synergistic broad-spectrum bactericidal activity against both Gram-positive and Gram-negative pathogens.
- Brand names
- IPOD-O
- Other names
- Cefpodoxime Proxetil & OfloxacinCefpodoxime Proxetil + Ofloxacincefpodoxime proxetil and ofloxacin
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)PBP (Penicillin-binding protein family)β-lactamase
Beyond the preview
Go deeper on cefpodoxime proxetil + ofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefpodoxime proxetil + ofloxacin.